GlassScriptPhysician profile
Anthony J Petelin
NPI 1063668531
$1,045.59
in general payments reported to CMS, 2019-2025
16 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $34.21 · 2021: $220 · 2022: $150 · 2023: $168 · 2024: $147 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $274.02 | 2021-2023 | Enbrel, Otezla |
| Abbvie INC. | $181.21 | 2021-2025 | |
| Celgene Corporation | $131.72 | 2019 | |
| Janssen Biotech, INC. | $120.11 | 2023-2024 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $73.00 | 2024 | Sotyktu |
| Leo Pharma INC. | $40.29 | 2020-2024 | Adbry |
| Genzyme Corporation | $29.26 | 2025 | |
| Sun Pharmaceutical Industries INC. | $27.72 | 2024 | |
| Organogenesis INC. | $24.77 | 2023 | Puraply |
| Genentech USA, INC. | $22.93 | 2021 | |
| Dompe US, INC. | $22.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.97 | 2019 | |
| Arcutis Biotherapeutics, INC. | $20.50 | 2025 | Zoryve |
| Misonix INC | $20.44 | 2021 | |
| Dermira, INC. | $19.22 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $16.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Petelin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.